| NCT01789723 | Non Hodgkin's Lymphoma | Drug: Fusilev|Drug: Folotyn | Spectrum Pharmaceuticals, Inc | Phase 1 | 2013-03-01 | 2013-07-23 |
| NCT01820091 | Non-Small Cell Lung Cancer | Drug: Folotyn|Drug: Fusilev | Spectrum Pharmaceuticals, Inc | Phase 1 | 2013-04-01 | 2013-09-03 |
| NCT02612857 | Dermatomyositis | Drug: IMO-8400 Dose Group 1|Drug: IMO-8400 Dose Group 2|Drug: Placebo | Idera Pharmaceuticals, Inc. | Phase 2 | 2015-11-01 | 2017-03-01 |
| NCT01364376 | Stomach Neoplasms | Drug: S-1; Oxaliplatin; 5-Fu; Leucovorin Calcium | Zhejiang University | | 2011-06-01 | 2016-08-20 |
| NCT01602016 | Autism Spectrum Disorder|Autistic Disorder|Autism|Asperger's Syndrome|Pervasive Development Disorders | Drug: Folinic Acid and placebo|Drug: Folinic Acid | University of Arkansas|Arkansas Children's Hospital Research Institute | Phase 2 | 2012-05-01 | 2017-01-05 |
| NCT02551380 | Autism Spectrum Disorder | Drug: FOLINORAL|Other: Placebo | Central Hospital, Nancy, France | Phase 2 | 2015-10-01 | 2016-06-15 |
| NCT02697058 | Metastatic Pancreatic Cancer | Biological: BAX2398 + 5-FU/calcium levofolinate|Drug: 5-FU/calcium levofolinate | Baxalta US Inc. | Phase 2 | 2016-03-01 | 2016-10-10 |
| NCT00877227 | Mild Hyperhomocysteinemia | Drug: 5-formyltetrahydrofolate (10 mg/ml) (Pharmachemie bv) | Radboud University | Phase 1 | 2003-01-01 | 2009-05-05 |
| NCT00719199 | Colorectal Cancer | Drug: IMO-2055|Drug: Cetuximab|Drug: FOLFIRI | EMD Serono | Phase 1 | 2009-01-01 | 2013-10-21 |
| NCT00729053 | Renal Cell Carcinoma | Drug: IMO-2055 | Idera Pharmaceuticals, Inc. | Phase 2 | 2004-06-01 | 2009-01-08 |
| NCT02363439 | Waldenstrom's Macroglobulinemia | Drug: IMO-8400 | Idera Pharmaceuticals, Inc. | Phase 1|Phase 2 | 2014-11-01 | 2017-02-06 |
| NCT00728936 | Hepatitis C | Drug: IMO-2125|Drug: placebo | Idera Pharmaceuticals, Inc. | Phase 1 | 2007-09-01 | 2012-05-15 |
| NCT00633529 | Non-Small Cell Lung Cancer | Drug: IMO-2055 | EMD Serono | Phase 1 | 2007-11-01 | 2013-10-21 |
| NCT02092909 | Waldenstrom's Macroglobulinemia | Drug: IMO-8400 | Idera Pharmaceuticals, Inc. | Phase 1|Phase 2 | 2014-03-01 | 2016-10-04 |
| NCT01700569 | Grade IV Astrocytoma|Glioblastoma | Drug: Temozolomide|Drug: folinic acid at pharmacological dose is the escalated drug|Radiation: High voltage radiation therapy (linear accelerator) | Institut Cancerologie de l'Ouest|Centre Antoine Lacassagne | Phase 1 | 2013-01-01 | 2016-08-30 |
| NCT02839915 | Autism Spectrum Disorder | Drug: Folinic Acid|Other: Placebo | Emory University|Arkansas Children's Hospital Research Institute|Harvard University | Phase 3 | 2016-11-01 | 2016-09-07 |
| NCT02506231 | Graft vs Host Disease|Allogeneic Hematopoietic Cell Transplantation|Mucositis | Drug: Folinic acid|Drug: Placebo | Rabin Medical Center | Phase 2|Phase 3 | 2015-10-01 | 2015-07-23 |
| NCT03052205 | Refractory Solid Tumors | Drug: IMO-2125 | Idera Pharmaceuticals, Inc. | Phase 1 | 2017-04-01 | 2017-02-13 |
| NCT00080990 | Unspecified Adult Solid Tumor, Protocol Specific | Drug: alvocidib|Drug: fluorouracil|Drug: oxaliplatin|Drug: leucovorin calcium | National Cancer Institute (NCI) | Phase 1 | 2004-02-01 | 2013-12-13 |
| NCT00001014 | Pneumonia, Pneumocystis Carinii|HIV Infections | Drug: Trimetrexate glucuronate|Drug: Sulfamethoxazole-Trimethoprim|Drug: Leucovorin calcium | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 | null | 2012-03-15 |
| NCT01622348 | Actively Extending Plaque Psoriasis|Moderate to Severe Plaque Psoriasis | Drug: IMO-3100|Drug: Saline for Injection|Drug: IMO-3100 | Idera Pharmaceuticals, Inc. | Phase 2 | 2012-05-01 | 2013-03-26 |
| NCT01576705 | Down Syndrome | Drug: thyroid hormone and folinic acid | Institut Jerome Lejeune|Ascopharm Groupe Novasco|Effi-stat|AnticipSante|LC2|BIOMNIS|University of Paris 5 - Rene Descartes|Inserm U954 (Nancy) | Phase 3 | 2012-04-01 | 2016-01-29 |
